in this issue

Open Access
Publisher Website
Google Scholar
Abstract
Nowadays, more patients presenting with metastatic breast cancer have relapsed following adjuvant or neoadjuvant chemotherapy, which often includes combinations of anthracyclines and taxanes. As the readministration of anthracyclines may be associated with reduced efficacy and significant cardiotoxicity, there is a need to develop non-anthracycline-containing regimens for the treatment of patients with advanced disease. In this issue, Mavroudis et al. [pp. 48–54] report the results of a study that aimed to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer. These authors report that the two regimens have similar efficacy but different toxic effects, and they conclude that either regimen can be used as front-line treatment of advanced breast cancer.

This publication has 0 references indexed in Scilit: